These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 20212252)
1. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99. Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252 [TBL] [Abstract][Full Text] [Related]
2. Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children's Cancer and Leukemia Study Group. Koizumi S; Fujimoto T Int J Hematol; 1994 Feb; 59(2):99-112. PubMed ID: 8018909 [TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group. Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605 [TBL] [Abstract][Full Text] [Related]
4. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors. Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717 [TBL] [Abstract][Full Text] [Related]
5. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. Laver JH; Kraveka JM; Hutchison RE; Chang M; Kepner J; Schwenn M; Tarbell N; Desai S; Weitzman S; Weinstein HJ; Murphy SB J Clin Oncol; 2005 Jan; 23(3):541-7. PubMed ID: 15659500 [TBL] [Abstract][Full Text] [Related]
6. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL. Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF; Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367 [TBL] [Abstract][Full Text] [Related]
7. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669 [TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study. Lange BJ; Blatt J; Sather HN; Meadows AT Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385 [TBL] [Abstract][Full Text] [Related]
9. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study. Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M; Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410 [TBL] [Abstract][Full Text] [Related]
10. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. Hutchinson RJ; Gaynon PS; Sather H; Bertolone SJ; Cooper HA; Tannous R; Wells LM; Heerema NA; Sailer S; Trigg ME; J Clin Oncol; 2003 May; 21(9):1790-7. PubMed ID: 12721256 [TBL] [Abstract][Full Text] [Related]
11. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576 [TBL] [Abstract][Full Text] [Related]
12. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U; J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786 [TBL] [Abstract][Full Text] [Related]
13. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG. van der Werff Ten Bosch J; Suciu S; Thyss A; Bertrand Y; Norton L; Mazingue F; Uyttebroeck A; Lutz P; Robert A; Boutard P; Ferster A; Plouvier E; Maes P; Munzer M; Plantaz D; Dresse MF; Philippet P; Sirvent N; Waterkeyn C; Vilmer E; Philippe N; Otten J Leukemia; 2005 May; 19(5):721-6. PubMed ID: 15744348 [TBL] [Abstract][Full Text] [Related]
15. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol. Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K; Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159 [TBL] [Abstract][Full Text] [Related]
16. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Mora J; Filippa DA; Qin J; Wollner N Cancer; 2003 Sep; 98(6):1283-91. PubMed ID: 12973853 [TBL] [Abstract][Full Text] [Related]
17. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma]. Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718 [TBL] [Abstract][Full Text] [Related]
18. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296. Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607 [TBL] [Abstract][Full Text] [Related]
19. B-lineage acute lymphoblastic leukemia of childhood. An institutional experience. Rivera-Luna R; Cardenas-Cardos R; Leal-Leal C; Navarro-Alegría I; Meza-Coria C; Gómez-Martínez R; Vega-Vega L Arch Med Res; 1997; 28(2):233-9. PubMed ID: 9204615 [TBL] [Abstract][Full Text] [Related]
20. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922. Tolar J; Bostrom BC; La MK; Sather HN Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]